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We here report molecular investigations of a missense mutation in the HSPE1 gene
encoding the HSP10 subunit of the HSP60/ HSP10 chaperonin complex that assists
protein folding in the mitochondrial matrix. The mutation was identified in an infant who
came to clinical attention due to infantile spasms at 3 months of age. Clinical exome
sequencing revealed heterozygosity for a HSPE1 NM_002157.2:c.217C>T de novo
mutation causing replacement of leucine with phenylalanine at position 73 of the HSP10
protein. This variation has never been observed in public exome sequencing databases
or the literature. To evaluate whether the mutation may be disease-associated we
investigated its effects by in vitro and ex vivo studies. Our in vitro studies indicated
that the purified mutant protein was functional, yet its thermal stability, spontaneous
refolding propensity, and resistance to proteolytic treatment were profoundly impaired.
Mass spectrometric analysis of patient fibroblasts revealed barely detectable levels
of HSP10-p.Leu73Phe protein resulting in an almost 2-fold decrease of the ratio of
HSP10 to HSP60 subunits. Amounts of the mitochondrial superoxide dismutase SOD2,
a protein whose folding is known to strongly depend on the HSP60/HSP10 complex,
were decreased to approximately 20% in patient fibroblasts in spite of unchanged SOD2
transcript levels. As a likely consequence, mitochondrial superoxide levels were increased
about 2-fold. Although, we cannot exclude other causative or contributing factors, our
experimental data support the notion that the HSP10-p.Leu73Phe mutation could be the
cause or a strong contributing factor for the disorder in the described patient.
Keywords: protein folding, molecular chaperones, mitochondrial proteins, neurological disorders, De novo
mutations, oxidative stress
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INTRODUCTION
Heat shock protein 10 (HSP10) and heat shock protein 60
(HSP60) are the constituents of the HSP60/HSP10 chaperonin
complex that assists folding of proteins in the mitochondrial
matrix space (Cheng et al., 1989; Hartman et al., 1992).
Chaperonins including the most thoroughly investigated
Escherichia coli GroEL/GroES complex constitute a subfamily
of the molecular chaperones characterized by the extraordinary
architecture of these complexes that provides an inner cavity
for folding of proteins (Horwich and Fenton, 2009; Hayer-Hartl
et al., 2016). The HSP60 subunits are organized in a double-
barrel structure that is built by two heptameric rings of 60 kDa
subunits stacked back-to-back (Nisemblat et al., 2015). The inner
cavity of the barrel initially binds unfolded proteins to the inner
wall. Subsequent binding of a heptamer of HSP10 subunits puts
a “lid” on the cavity. Binding of ATP molecules to the HSP60
subunits results in conformational changes of the HSP60/HSP10
complex (Saibil et al., 2013). Finally, timed ATP hydrolysis
triggering additional conformational changes of the complex
leads to dissociation of the HSP10 lid and discharge of the
enclosed protein. One or several rounds of this process facilitate
folding of interacting proteins. In vitro refolding studies have
shown that under non-permissive conditions (i.e., spontaneous
folding is minimal) the presence of HSP10 is strictly essential
for efficient folding of model substrate proteins (Schmidt et al.,
1994).
Together with other chaperones and proteases, the HSP60/
HSP10 complex forms the protein quality control (PQC) system
in the mitochondrial matrix and its expression is regulated
by the mitochondrial unfolded protein response and the heat-
shock responses (Aldridge et al., 2007). PQC systems, also
known as proteostasis networks (Balch et al., 2008), consist of
molecular chaperones and proteases that collectively maintain
the functional proteome by, on one hand assisting protein
folding and on the other hand removing misfolded proteins,
thus promoting folding to the native state and minimizing
deleterious effects of misfolded proteins. PQC systems play a
decisive role in many diseases including protein aggregation
diseases like Alzheimer’s and Parkinson’s disease as well as
protein misfolding diseases like phenylketonuria and medium-
chain acyl-CoA dehydrogenase deficiency (Gregersen et al., 2006;
Chen et al., 2011).
The mitochondrial matrix proteome is estimated to consist
of at least 500 proteins (Rhee et al., 2013) that maintain
mitochondrial ATP production, the energy fuel of cells.
Furthermore, a plethora of other synthetic and important
catalytic and regulatory functions (Raimundo, 2014) takes place
in the mitochondrial matrix, which is the most protein-dense
compartment in the cell.
The human HSP10 protein is encoded by theHSPE1 gene that
is located in a head to head arrangement with the HSPD1 gene
encoding HSP60. Both genes are transcribed under control of a
bidirectional promoter localized between the genes (Ryan et al.,
Abbreviations: CSF, cerebrospinal fluid; PQC, protein quality control; SRM,
selected reaction monitoring.
1997). The head to head arrangement of the HSPD1 and HSPE1
genes appears to secure transcription of both chaperonin genes
at a fixed ratio and it is conserved from Caenorhabditis elegans
to humans. Organization of the E. coli groEL and groES genes in
an operon under control of a common promoter likewise has the
same purpose (Ryan et al., 1997).
The neurological disorders hereditary spastic paraplegia
SPG13 (Hansen et al., 2002) and MitCHAP-60 disease (Magen
et al., 2008) are caused by missense mutations in theHSPD1 gene
(reviewed in Bross and Fernandez-Guerra, 2016). Hereditary
spastic paraplegia SPG13 (OMIM #605280) is a late onset,
autosomal dominantly inherited disorder that primarily affects
motor neurons with the longest axons in the spinal cord.
In contrast, the autosomal recessively inherited MitCHAP-60
disease (OMIM #612233) is linked to a much more severe
fatal neurodegenerative disorder of early onset causing death
within the first two decades of life and associated with highly
pronounced cerebral hypomyelination. Investigations of the
purified mutant HSP60 proteins associated with both diseases
have indicated that these HSP60 mutant proteins are apparently
normally incorporated into HSP60 ring complexes, but display
reduced ATP hydrolysis activity and impaired refolding activity
(Bross et al., 2008; Parnas et al., 2009).
In vivo studies in mice have shown that knock-out of both
alleles of the Hspd1 gene is embryonally lethal (Christensen
et al., 2010). However, mice heterozygous for the knock-out allele
recapitulate features of hereditary spastic paraplegia with late
onset motoneuron disorder (Magnoni et al., 2013). These mice
display swollen mitochondria in spinal cord, deficient complex
III activity in spinal cord and brain cortex as well as increased
protein carbonylation in these tissues suggesting increased ROS
production (Magnoni et al., 2014). Importantly, complex III
deficiency was found to be associated with decreased levels of
the complex III subunit UQCRC1 and increased ROS levels
appear to be due to impaired folding and increased turnover
of the matrix superoxide dismutase SOD2. This suggested that
HSP60 haploinsufficiency caused impaired folding of certain
mitochondrial proteins thus leading to a variety of impaired
functions. The different phenotypes caused by the different
HSPD1 mutant alleles and inheritance modes suggests that
different types and degrees of disturbances of this system cause
distinct phenotypic manifestations. The study of these genetic
diseases is thus a unique opportunity to enlighten these basic
mechanisms in humans and for pinpointing modes how to target
these mechanisms for the treatment of diseases.
In the present study we investigated a patient with a history
of infantile spasms, hypotonia, developmental delay, a slightly
enlarged liver, macrocephaly, and mild non-specific dysmorphic
features. Clinical exome sequencing revealed heterozygosity for
a de novo point mutation in the HSPE1 gene triggering studies
of possible effects of the mutation at protein level and at
cellular level in patient fibroblasts. As potentially disease-causing
mutations in the HSPE1 gene so-far only have been observed
in this single patient, we cannot fully exclude other genetic
and/or environmental causes, However, our results show that the
investigated mutation causes malfunction of the HSP60/HSP10
complex. Taken together with the knowledge on diseases caused
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by mutations in the gene encoding the HSP60 subunit we make
the case for a mutation disease relationship.
MATERIALS AND METHODS
Clinical Patient Analysis
The patient, a male infant, came to clinical attention due
to infantile spasms at 3 months of age. Subsequent clinical
investigations revealed hypotonia, developmental delay, a slightly
enlarged liver, macrocephaly, and some mild nonspecific
dysmorphic features. For more detailed description of the clinical
picture see Extended clinical patient information in Appendix.
Metabolic analysis on plasma, urine and cerebrospinal fluid
(CSF) showed an unusual urine amino acid profile that did not
fit a pattern of known metabolic disorders. Data on compounds
that deviated from the control range in at least one analysis
are shown in Table 1. It was characteristic for the metabolite
analyses that values varied between repeated analyses suggesting
that environmental factors and conditions may influence the
metabolic profiles. Plasma amino acids and urine organic acids
were overall normal. Urine dicarboxylic acids were slightly
increased in two out of three analyses, which could indicate a fatty
acid oxidation disorder. However, a plasma acyl-carnitine profile
that had been determined prior to the first biochemical lab tests
at age 6 months, showed no abnormalities.
Interestingly, the pyridoxal 5′-phosphate concentration in
CSF was just below the reference interval and defective
pyridoxine metabolism has been shown to cause seizures
(Mills et al., 2006; Plecko et al., 2007). Furthermore, gamma
aminobutyrate was elevated in urine, which could indicate GABA
transaminase deficiency. GABA transaminase is dependent on
pyridoxal 5′-phosphate and hence also related to the seizure
symptoms. Imaging of the patient’s brain was carried out with
and without contrast (not shown), but no significant interval
changes were detected, nor were there any mass effect, infarct,
hemorrhage, demyelination or hydrocephalus. Because of mild
hepatosplenomegaly noted at one point, lysosomal enzyme
screening was carried out but results were inconspicuous.
Chromosomal microarray analysis showed a de novo 0.146
Mb deletion at 17q23.3 and a 0.316 Mb gain at 17q25.1 that
was maternally inherited. The deletion involved a single gene,
TANC2, which is most expressed in the adult brain and has very
low expression in the fetal brain. It has not been associated with a
known disorder to date. A review of the genes involved in the
duplication did not show any genes that were suspected to be
associated with the clinical features of this patient.
Cell Culturing
The patient fibroblast line was derived from a skin biopsy.
Informed consent from the parents was obtained at the time
of the skin biopsy and documented in the patient’s medical
record. Information included that the primary research focus
would be to study the effect of the variant on the function
of HSPE1 and the potential impact it would have on the
patient’s clinical phenotype. Written informed consent from
the family was also obtained. The investigation was performed
in accordance with regulations set by the Danish National
TABLE 1 | Selected metabolite data.
Compound [mmol/mmol
creatine]
Control range
Low High
Urine organic
acids
3OH-Buturic 25/4/0 0 10
Glutaric 6/3/2 0 5
Acetoacetic 11/3/2 0 2
Suberic 12/7/7 0 7
OH-Dicanedioic 7/5/5 0 2
Methylmalonic 2/6/5 0 5
Octanoic 0/9/7 0 2
Pyrovic 7/18/23 0 22
Urine amino
acids
Gamma-aminobutyrate 143/71/107 0 11.9
Hydroxy-lysine 5018/2273/1937 1.1 11
Alpha-aminoadipic 212/64/202 5.1 30.3
Beta-alanine 510/115/473 0 33.6
Taurine 897/319/647 617 428.7
Glutamine 181/173/151 75.8 176.7
Halfcysteine 74/111/227 15.4 160.6
Lysine 33/23/101 21.4 96.2
Compound µmol/L Control range
Low High
Cerebrospinal
fluid
Pyridoxal 5-Phosphate 22 23 64
Free sialic acid 28 2 22
Total sialic acid 60 8 50
Urine organic acids and urine amino acid concentrations were measured as mmol/mol
creatinine. Values from 3 measurements are given separated by “/.” Organic acids
and amino acids concentrations in cerebrospinal fluid were measured as µmol/L. Only
compounds that differed from control samples in at least one measurement are shown.
Committee on Health Research Ethics. Patient skin fibroblasts
and three anonymized age-matched control fibroblasts were
cultured according to standard procedures. In brief, fibroblasts
were maintained in Dulbecco’s modified Eagles media (DMEM),
supplemented with 10% (v/v) fetal bovine serum, 29 mg/mL of L-
glutamine (Leo Pharmaceutical), and 1% penicillin/streptomycin
(Leo Pharmaceutical) at 37◦C and 5% CO2. Fibroblasts were
negative for Mycoplasma sp. and tests were performed routinely
(PromoKine, Heidelberg, Germany)
DNA and RNA Purification
High molecular weight genomic DNA was isolated from whole
blood by QIAcube (QIAGEN) according to manufacturer’s
protocol at UCLAMolecular Diagnostics Laboratories. RNA was
isolated from fibroblast pellets by Trizol (Life Technologies)
according to manufacturer’s description. Quality and amounts
of the DNA and RNA preparations was measured by NanoDrop
Spectrophotometer (Thermo Scientific), Qubit (ThermoFisher
Scientific), and agarose gel electrophoresis.
DNA Sequencing
Clinical exome sequencing and data analysis was performed at
the UCLA Clinical Genomics Center on the patient and both
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parents (i.e., Trio-CES) following the CLIA (Clinical Laboratory
Improvement Amendments) and CAP (College of American
Pathologists) validated protocols (Lee et al., 2014). Briefly, exome
capture was performed using the Agilent SureSelect Human All
Exon 50 Mb kit (Agilent technologies) and HiSeq2000 (Illumina)
as 50 bp paired end run. In the patient, total 13,377,501,340 bases
of sequence were generated and uniquely aligned to the human
reference genome, generating a mean depth of coverage of 150x
per base within the RefSeq protein coding bases of the human
genome with 94% of the bases covered at greater than 9 reads.
Parental samples were sequenced at similar depth of coverage
(mother: 159X; father: 152X). The HSPE1 de novo variant was
confirmed by Sanger sequencing at the UCLA Orphan Disease
Testing Center (ODTC) in the trio.
Sanger sequencing of fibroblast genomic DNA and PCR
products from cDNA derived from fibroblast RNA was
performed using Big Dye R© Terminator v.1.1 Cycle Sequencing
Kit (Life Technologies, USA) and analysis with the Genetic
Analyzer 3500 Dx (Life Technologies, USA). Sequence data were
evaluated with Gensearch software (PhenoSystems, Belgium).
Selected Reaction Monitoring (SRM)
Fibroblasts were lysed in 100 mM ammonium bicarbonate and
1M urea with ultrasonication (Branson Sonifier 250, Branson
Ultrasonics Corp) at output control 3 and 30 % duty cycle for
three cycles of five pulses, with 1 min on ice between each
cycle. Lysates were centrifuged at 13,000 g for 30 min at 4◦C.
Protein concentration of the soluble fraction was measured by
Bradford Protein assay (Bio-Rad) and 30 µg were used for SRM
analysis. Relative quantification of peptides was carried out using
a modified version of the SRM assay described in Fernández-
Guerra et al. (2014). In brief all targeted proteins were monitored
by detection of 2–5 tryptic peptides. Defined amounts of heavy
labeled synthetic peptide analogs were spiked into the samples
and used for relative quantification. The summed fragment
ion peak areas for each peptide were normalized to the signal
responses from the corresponding spiked heavy-labeled peptide
standards. The means of the ratios for each peptide measured
in control fibroblasts were set to 100% and the means for the
patient fibroblast samples were expressed as the percentage of
these. Samples from 3 independently grown control fibroblasts
and 3 parallel cultures of patient fibroblasts were analyzed.
cDNA Analysis and PCR
cDNA was synthesized from 1 µg of RNA using the iScriptTM
cDNA Synthesis Kit (BioRad). Subsequent qRT-PCR analysis
was performed using TaqMan gene expression assays for HSPE1,
HSPD1, SOD2, and ACADM and analyzed on ABI StepOne
plus (Applied Biosystems) essentially as described in Hansen
et al. (2008). Relative transcript levels were calculated using the
standard curve method.
For sequencing of the mutation site on genomic DNA, a
fragment was amplified with primers situated in intron 2 and
the 3′-UTR of exon 4 of the HSPE1 gene, respectively. For
sequencing of the mutation site in cDNA derived from patient
or control fibroblasts isolated RNA was amplified using primers
in exon 2 and the coding region of exon 4. For primer sequences
see Supplementary Table S1. Correct size of PCR products was
analyzed by agarose gel electrophoresis.
In vitro Synthesis and Mitochondrial Import
Assay
In vitro transcription/translation and subsequent import into
mitochondria was performed as described in Bross et al. (2003)
with minor modifications. Briefly, cDNA sequences for wild type
HSPE1 andHSPE1_ c.217C>T in pcDNA3.1 plasmids (Eurofins)
were used to produce HSP10-p.wt and HSP10-p.Leu73Phe
protein by in vitro transcription/translation in rabbit reticulocyte
lysate systems (TNT T7 kit, Promega) in the presence of [35S]-
methionine as recommended by the supplier. Mitochondria were
isolated from fresh mouse liver. Import mixtures were incubated
at 37◦C and aliquots were removed immediately after addition
of the labeled HSP10 and after 15, 30, and 60 min. Fractions of
the soluble proteins from mitochondrial lysates were analyzed
by SDS PAGE (Criterion TGX gel, Any kDa, Biorad). Gels were
stained with Coomassie, dried, exposed to phosphor imaging
screens overnight and radiolabeled proteins were visualized by
phosphor imaging (Typhoon, GE Healthcare).
Cloning, Mutagenesis and Purification of
HSP10-Leu73Phe Protein
Human HSP10 cDNA (GenBank accession no. P61604) was
inserted into the pET22b(+) expression plasmid (Novagen) using
NdeI and XhoI restriction sites. A stop codon was inserted at
the end of the cDNA sequence to generate a construct that
does not contain a C-terminus His-tag. The Leu73Phe mutation
was inserted into the HSP10 gene by site-directed mutagenesis
according to the protocol of Stratagene, using the primers
mHSP10L73F_F and mHSP10L73F_R (for primer sequences see
Supplementary Table S1).
HSP10 was expressed as described in Parnas et al. (2009)
and purified as follows: the cell pellet was resuspended (1:10
w/v) in a buffer containing 20 mM Tris-HCl pH 7.7, 5 mM
MgSO4, 1 mM DTT, 1500 units DNase. Cells were homogenized
and passed through a microfluidizer. Immediately after lysis,
PMSF (0.5 mM) and 1 µg/ml of each of the following
protease inhibitors (Sigma) were added: Pepstatin, Chymostatin,
Antipain, Leupeptin, and Aprotinin. Debris was removed by
centrifugation for 30min at 35,000 g. The supernatant was loaded
onto a RESOURCE Q column (GH Healthcare) equilibrated
with buffer A (20 mM Tris-HCl pH 7.7, 0.1 mM EDTA, and 1
mM DTT). Unbound proteins were collected from the column
and dialyzed over night against buffer B (20 mM MES pH
6.6 and 0.1 mM EDTA). The protein was then loaded on a
SOURCE-S column (GH Healthcare) equilibrated with buffer
B. Bound proteins were eluted from the column with a linear
gradient of 0–500 mM NaCl (in buffer B). HSP10-enriched
fractions were collected and concentrated. The protein was then
loaded on a Superdex 200 prep grade gel-filtration column
(Pharmacia) equilibrated with buffer C (50 mM Tris-HCl pH
7.7 and 100 mM NaCl). Fractions containing heptameric HSP10
were concentrated to approximately 40 mg/ml and flash-frozen
in liquid nitrogen for storage. All stages were carried out at 4◦C.
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Analysis of tryptic peptides by a nano Liquid-Chromatography
system (Ultimate 3000, Dionex) coupled to a mass spectrometer
(Q Exactive, Thermo Fisher Scientific) through an EASY-Spray
nano-electrospray ion source (Thermo Scientific) confirmed high
purity.
Malate Dehydrogenase (MDH) Refolding
Assay
Refolding of HCl-denatured MDH was carried out as previously
described by Bonshtien et al. (2009).
Thermal Unfolding/Refolding Kinetics
Temperature-dependent denaturation/renaturation experiments
were performed using a ChirascanTM CD (CircularDichroism)
spectrometer as described by Vitlin Gruber et al. (2013).
Limited Proteolysis Assay
Purified HSP10-p.wt or HSP-p.Leu73Phe protein at 0.1 mg/ml
in 100 mM Tris-HCl (pH 7.8) was incubated at 37◦C. Trypsin
was added to a final concentration of 0.01 mg/ml (molar ratio
HSP10:trypsin 10:1). Samples were taken immediately before and
2, 10, 25, 60, and 120 min after addition of trypsin. Samples
were quenched by addition of SDS PAGE sample buffer and
incubation at 95◦C for 2 min. As control, series without addition
of trypsin were performed. Samples were subjected to SDS PAGE
and proteins stained with Coomassie.
For analysis of the content of HSP10 bands from SDS PAGE,
Coomassie–stained bands were excised and peptides extracted as
described (Edhager et al., 2014). Peptides were analyzed using a
nano Liquid-Chromatography system (Ultimate 3000, Dionex)
coupled to a mass spectrometer (Q Exactive, Thermo Fisher
Scientific) through an EASY-Spray nano-electrospray ion source
(Thermo Scientific).
Image Cytometry and Bioenergetics
Measurements
All cytometric fluorescent measurements were performed using
the NC-3000 image cytometer (Chemometec) as described
in Fernandez-Guerra et al. (2016). Mitochondrial oxygen
consumption rate profiling assays of cultured fibroblasts were
performed using a Seahorse XFe96 extracellular flux analyzer and
the Mito Stress test kit (Seahorse Bioscience) as recommended
by the supplier with the following modifications: 15,000 cells per
well were seeded 24 h before analysis and FCCP was added at
1 µM final concentration. Oxygen consumption rate (OCR) was
normalized to total protein amount measured in each well after
the analysis using the Bradford Protein assay (Bio-Rad).
Mitochondrial Morphology
The mitochondrial morphology of fibroblast from the patient
and healthy individuals was analyzed using Mitotracker Green
FM (Molecular Probes, Life Technologies). Fibroblasts from the
patient and healthy individuals were seeded at 50% confluence in
6-well plates (Nunc, Roskilde, Denmark) 24 h before the analysis.
The fibroblasts were stained with 100 nM Mitotracker Green
(Molecular probes) for 30 min at 37◦C. Pictures were obtained
with the EVOS FLoid Cell Imaging Station (Life Technologies)
with the standard green channel of the instrument (482/18 nm
excitation and 532/59 nm emission). The image was adjusted
for contrast with the software of the instrument; no further
processing of the image was done.
RESULTS
Clinical Exome Sequencing Reveals a
De novo Mutation in the HSPE1 Gene
Encoding the HSP10 Subunit of the
Mitochondrial HSP60/HSP10 Chaperonin
Complex
As clinical and metabolic investigations of the patient did not
reveal the causative factor of the symptoms (for information on
the patient see Materials and Methods Clinical patient analysis
and Appendix “Extended clinical patient information”), whole
exome sequencing on the patient and the parents was performed
as the next step. No relevant mutations were found in a list of
758 genes (Supplementary Table S2) annotated with keywords
relevant for the disease phenotype. However, further analysis
of the exome sequencing data revealed a de novo heterozygous
missense variation, c.217C>T [p.Leu73Phe], in the HSPE1 gene
encoding the mitochondrial co-chaperonin HSP10 that forms
part of the HSP60/ HSPSP10 chaperonin complex. Presence
in the patient and absence in the parents was confirmed by
Sanger sequencing. The detected variation has to our knowledge
never before been reported in the literature or publicly accessible
genetic databases and the HSPE1 gene has not previously been
associated with a human disorder. Variation in the third position
of the CTC codon for the mutated leucine-73 of the HSPE1 gene
(to T or G) resulting in codons that also specify leucine has been
observed as documented by the Exome Aggregation Consortium
(ExAC; Cambridge, MA; accessed December 2015). Investigation
of the HSP10 mutation in silico using the prediction tool
PolyPhen2 predicted the mutation to be “possibly damaging,”
with a score of 0.954 on a scale from 0 to 1. Similarly, the SIFT
prediction tool (Ng and Henikoff, 2001) predicted the mutation
to be “damaging.”
Inspection of the crystal structure of the HSP60/HSP10
complex (Figure 1) showed that themutated leucine-73 is located
distantly from the mobile loop region that mediates interaction
with HSP60 and the mutation is thus not expected to directly
affect this interaction. Leucine-73 is facing the hydrophobic
core made by the beta-sheets building the HSP10 main body
(Figure 1). When we examined leucine-73 solvent accessibility
using the PISA program (Krissinel andHenrick, 2007) we noticed
that the average accessible surface area (ASA) of this residue is
only 1.36 Å2 indicating that it is tightly packed. The neighboring
Leu72 for instance has an average ASA of 53.3 Å2, while Leu97
that is positioned between HSP10 subunits has an ASA of more
than 120 Å2.
In vitro Studies of the Mutation Effect
To explore the effects of the mutation on structural and
functional properties of the co-chaperonin, we performed
in vitro studies on purified HSP10-p.Leu73Phe protein following
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FIGURE 1 | Position of Leucine-73 in the HSP60/HSP10 complex structure. (A) HSP60-HSP10 symmetric football complex shown in cartoon representation.
HSP60 subunits are in cyan and HSP10 subunits are in green. One HSP60 subunit (subunit D) and its interacting HSP10 subunit (subunit R) are emphasized (purple
and blue respectively). The mobile loop of subunit R is in red. Leucine-73 residue is depicted in yellow with space filling representation. (B) Enlarged view of the boxed
area in (A) displaying HSP10’s subunit R. Color scheme as in (A). Leucine-73 and its interacting residues at the hydrophobic core of HSP10 (green) are presented as
sticks. (C) Enlarged view of the boxed hydrophobic core of HSP10 from figure (B). Leucine-73 and its interacting residues are labeled. Leucine-73 is facing the
hydrophobic core made by the beta-sheets building HSP10 main body. In addition, analysis of Leucine-73 interactions in all HSP10 subunits using the PISA and PIC
servers (Krissinel and Henrick, 2007; Tina et al., 2007) showed that Leucine-73 is tightly packed in the core of the HSP10 molecule. It has an average accessible
surface area of only 1.36 Å2, while it interacts with the following residues of the core: Val18, Leu42, Ala44, Val71, Pro74, Phe91, and Ile96. Illustrations were
generated using the PyMOL program (The PyMOL Molecular Graphics System, version 1.5.0.4; Schrödinger, LLC; available at www.pymol.org), with PDB ID: 4PJ1.
recombinant expression in bacteria. We analyzed the function of
HSP10-p.Leu73Phe in vitro by testing its ability to assist HSP60 in
refolding of malate dehydrogenase (MDH). MDHwas denatured
and diluted into a solution with HSP60 to allow its binding to
the chaperonin. Then ATP and different concentrations of either
HSP10-p.wt (Figure 2A) or HSP10-p.Leu73Phe (Figure 2B)
were added to let the folding reaction proceed. Surprisingly,
the results showed that the HSP10-p.Leu73Phe protein was fully
active and even had a tendency to display slightly faster kinetics
in assisting MDH refolding. However, when comparing the
different HSP10 concentrations, we noticed that the reaction
with HSP10-p.wt was already saturated at 2.5 µMHSP10 protein
whereas HSP10-p.Leu73Phe had to be present at 5µM to saturate
the reaction (Figures 2A,B).
We then investigated the thermal stability of the HSP10-
pLeu73Phe protein in vitro. Thermal unfolding and refolding
of mutant and wild type HSP10 proteins was monitored by CD
spectroscopy. Figure 2C shows a representative experiment. The
HSP10-p.Leu73Phe protein unfolds with a Tm of only 59◦C
compared to HSP10-p.wt that displays a Tm of approximately
73◦C (Figure 2C; stippled lines). A 14◦ difference between
the Tm’s of wild type and mutant HSP10 would result in a
reduction of the free energy of unfolding of approximately 3 kcal
(Greenfield, 2006). Considering that the free energy difference
between the unfolded and folded conformations of proteins
is in the range of 5–20 kcal (Pace, 1990), we conclude that
the conformational stability of the HSP10 mutant protein is
significantly decreased.
We also examined the reverse reaction of refolding wild type
and mutant HSP10 by gradually decreasing the temperature
from 90◦ to 25◦C. Both proteins spontaneously refold upon
decreasing the temperature (Figure 2C; solid lines). The Tm
of refolding of both the wild type and mutant HSP10 has
shifted to lower temperatures compared to their respective
Tm for unfolding. Interestingly the HSP10-p.Leu73Phe protein
regained a lower level of refolding at 25◦C (approximately 80%)
compared to HSP10-p.wt (approximately 95%). Altogether, these
results suggest that the Leu73Phe mutation negatively affects the
conformational stability of the HSP10 protein and impairs its
spontaneous refolding.
Decreased conformational stability should render the HSP10-
p.Leu73Phe protein more vulnerable to proteolytic attack. To
test this we performed a limited proteolysis experiment of the
HSP10-p.Leu73Phe protein at physiological temperature and
pH. Purified wild type and mutant HSP10 were incubated at
37◦C and pH 7.8 with trypsin for different time periods. Both
the wild type and the mutant HSP10 proteins were trimmed
to a shorter core fragment (HSP10∗) shortly after addition of
trypsin (Figure 2D). The core fragment band of HSP10-p.wt was
largely stable to further attack by trypsin for up to 2 h whereas
the HSP10-p.Leu73Phe core fragment band was continuously
degraded resulting in strongly reduced levels already after 1 h
and absence of the band after 2 h incubation (Figures 2D,E).
This suggests that the core fragment is much more susceptible
to proteolytic degradation when it carries a phenylalanine at the
mutation site than when it carries the wild type leucine.
To elucidate which part of HSP10 was lacking in the
trimmed core fragments, we performed mass spectrometric
analysis of the excised full-length and core HSP10 bands
(Supplementary Figure S1). Both the full-length and the core
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FIGURE 2 | In vitro properties of recombinantly produced HSP10-p.Leu73Phe. (A,B) Refolding kinetics of denatured MDH. HCl-denatured MDH (0.33 mM)
was refolded at 30◦C with HSP60 (10 µM), ATP (1 mMol/L) and the indicated concentrations of wild type (A) or p.Leu73Phe mutant (B) HSP10. Refolding is
expressed as the percentage of MDH activity before denaturation. (C) Thermal unfolding/refolding kinetics of wild type and p.Leu73Phe mutant HSP10. Folding status
was monitored by following the circular dichroism signal at 222 nm. 0.3 mg/ml HSP10-p.wt or HSP10-p.Leu73Phe in buffer containing 50 mM Tris-HCl pH 7.7 and
100 mM NaCl were analyzed. The experiments were carried out by varying the temperature from 25 to 90◦C (stippled lines; u = unfolding) and back to 25◦C (solid
lines; r = refolding). Ellipticity was measured with 2◦C intervals, 180 s setting time and 120 s time per point. (D) Limited proteolysis of HSP10 proteins with trypsin.
HSP10-p.wt and HSP10-Leu73Phe at 0.1 µg/ml in 100 mM Tris-HCl (pH 7.8) were incubated at 37◦C with or without addition of trypsin at a stoichiometric ratio of
1:10 (trypsin: HSP10). Proteolysis was stopped with addition of SDS PAGE sample buffer at the time points indicated and proteins were separated by SDS PAGE and
stained with Coomassie. The positions of full-length HSP10 and HSP10 core fragment are indicated. (E) Quantification of the band-intensities from the
Coomassie-stained gel shown in (D). (F) Import kinetics of wild type and p.Leu73Phe mutant HSP10 into isolated mouse liver mitochondria. The HSP10 proteins were
synthesized and radioactively labeled using a reticulocyte lysate system programmed by plasmids carrying the respective cDNAs as described in Materials and
Methods. Translated proteins were added to freshly isolated mouse liver mitochondria and incubated at 37◦C. Aliquots were taken at the time points indicated, and
mitochondria were trypsin-treated and reisolated. Aliquots were run on SDS PAGE followed by phosphorimaging. T: aliquot from the in vitro translation reaction.
bands from wild type and mutant HSP10 showed robust MS
signals for the peptides comprising amino acids 41–54 and 71–
80 (peptide containing the mutation site). However, the peptide
comprising amino acids 9–15 (FLPLFDR) was clearly present in
the full-length band yet strongly decreased in the core bands,
suggesting that low amounts of trypsin trim off N-terminal parts
in both the wild type and the mutant HSP10 protein.
To rule out the possibility that the mutation impairs import
of mutant HSP10 protein, we compared import of the in vitro
labeled HSP10 wild type and mutant proteins into isolated
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mouse liver mitochondria. Aliquots were taken at the time points
indicated and imported proteins were analyzed by SDS PAGE
and phosphorimaging after reisolation of the mitochondria.
Figure 2F shows the band pattern from a representative
experiment. To our surprise the HSP10-p.Leu73Phe protein was
clearly imported more efficiently than the wild type HSP10
protein. Adding the HSP10 proteins to the import mixture in
unfolded conformation after precipitation and resuspension in
denaturant resulted qualitatively in the same picture (data not
shown).
The Effects of the HSP10 Mutation in
Patient Fibroblasts
To evaluate the consequences of the conformational
destabilization of HSP10 by the p.Leu73Phe mutation in vivo
we turned to a cellular model system. A fibroblast culture
was established from a skin biopsy of the patient. We first
confirmed heterozygosity of the HSPE1: c.217C>T mutation
by Sanger sequencing of genomic DNA isolated from the
fibroblasts (Figure 3A). To elucidate whether the c.217C>T
mutation affects transcript levels we isolated RNA from the
fibroblast culture. Sequencing of the PCR product amplified
from the reverse transcribed RNA (Figure 3B) showed a very
similar tracing pattern around the mutation site as sequencing
of the PCR product amplified from genomic DNA from the
patient (Figure 3A). The peaks for both the C and the T at
position 217 had comparable heights in Sanger sequencing of
both genomic DNA and cDNA suggesting that roughly half
of the HSPE1 transcripts in the patient fibroblasts carried the
mutation. The primers used for amplification of the cDNA
were localized in exons 2 and 4, respectively, surrounding the
mutation site in exon 3. The sequence reads of the junctions
between exons 2 and 3 and between exons 3 and 4 were as
expected indicating that splicing was unaffected by the mutation.
qRT-PCR analysis of HSP10 and HSP60 transcript levels showed
no significant differences between patient and control fibroblasts
(Supplementary Figure S1). Taken together, this is consistent
with the notion that the HSPE1:c.217C>T mutation does not
significantly affect transcript levels or splicing.
To detect and quantitate the steady state levels of the HSP10-
p.Leu73Phe protein in fibroblasts of the patient we applied a
targetedmass spectrometric approach known as selected reaction
monitoring (SRM) using heavy-labeled synthetic peptides as
internal standards. Very small amounts of mutant HSP10-
p.Leu73Phe protein were present in fibroblasts from the patient.
Identification of this peptide was based on its fragmentation
pattern that was the same as that of the heavy labeled synthetic
peptide that had been spiked into the sample (Figure 3C). No
corresponding peptide with such a pattern was detectable in
control fibroblasts (data not shown). This indicated that small
amounts of mutant HSP10-p.Leu73Phe protein were present in
fibroblasts from the patient.
We then quantitated the total amounts of wild type and
mutant HSP10 protein in patient and control fibroblasts using
two peptides present in both the wild type and the HSP10-
p.Leu73Phe protein (peptides 1 and 2 in Figure 3D). SRM
analysis showed that the amounts of the HSP10 peptides 1 and
2 in the patient fibroblasts were decreased to approximately
50% as compared to the controls (Figure 3E). Measurement of
the wild type peptide spanning the mutation site (peptide 3)
showed only slightly lower relative amounts than peptides 1
and 2 (approximately 40% compared to approximately 50% for
peptides 1 and 2) in the patient fibroblasts compared to the
control fibroblasts. Taken together, our data strongly suggests
that the majority of the HSP10 protein present in patient
fibroblasts represents wild type HSP10 protein expressed from
the wild type allele.
We have previously observed decreased SOD2 protein levels
due to misfolding and degradation of SOD2 protein followed
by increased oxidative protein damage (protein carbonylation)
in a mouse model for hereditary spastic paraplegia due to
HSP60 haplosufficiency (Magnoni et al., 2013). As our present
investigations had shown half levels of HSP10 protein in
fibroblasts from our patient, we speculated that this might
also affect SOD2 protein amounts and superoxide levels. Again
using SRM mass spectrometry with heavy labeled peptides as
standards, we quantified SOD2 in cell lysates from patient
and control fibroblasts. In parallel we quantified the complex
partner HSP60, the fatty acid oxidation enzyme medium-chain
acyl-CoA dehydrogenase (MCAD) that previously had been
shown to interact with the HSP60/HSP10 complex (Saijo et al.,
1994; Saijo and Tanaka, 1995) and the mitochondrial outer
membrane protein VDAC, which was not expected to interact
with the HSP60/HSP10 complex. We found comparable protein
levels for HSP60, MCAD, and VDAC in patient and control
fibroblasts (Figure 4A). However, the protein level of SOD2
was reduced to approximately 20% in the patient fibroblasts
compared to controls. RT-qPCR analysis showed that SOD2
mRNA transcript levels, like those for the HSP60 and MCAD
mRNAs, were similar in the fibroblasts from patient and controls
(Supplementary Figure S2). Hence, decreased SOD2 protein
levels were not due to decreased SOD2 transcript levels.
Decreased SOD2 protein levels would be expected to result
in increased superoxide levels in the mitochondrial matrix.
Indeed, when measuring mitochondrial superoxide with the
fluorescent probe MitoSOX we observed an approximately
2-fold increase in average MitoSOX fluorescence intensity in the
patient fibroblasts compared to control fibroblasts (Figure 4B).
In an attempt to identify further functions that may be affected
we also evaluated a number of cellular and mitochondria-
related phenotypes of the patient fibroblasts. Fluorescence
microscopic analysis of mitochondria labeled with Mitotracker
green revealed no morphological differences between
patient and control fibroblasts (Supplementary Figure S3).
Furthermore, no significant differences between patient
and control fibroblasts were observed in assays for
cellular viability (Supplementary Figure S4A), overall
oxidation state measured as the level of reduced thiols
(Supplementary Figure S4B), and mitochondrial membrane
potential (Supplementary Figure S4C). We finally analyzed
OCR as a measure for mitochondrial respiratory chain activity
using a Seahorse extracellular flux analyzer. No significant
differences in basal OCR, reserve capacity, and ATP-linked
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FIGURE 3 | Analysis of DNA, RNA, and protein in patient fibroblasts. (A) Confirmation of c.217 C > T mutation in patient fibroblasts. A fragment spanning the
mutation site was amplified by PCR and analyzed by Sanger sequencing. Yellow highlighting indicates position c.217 and bases are indicated below: top line depicts
bases found by sequencing, lower line shows reference sequence. (B) Sequencing of transcripts. Total RNA was isolated from control and patient fibroblast and used
for cDNA synthesis followed by PCR amplification of a fragment comprising the mutation site. PCR fragments were analyzed by Sanger sequencing. (C) Detection of
the mutant peptide in patient fibroblasts by SRM-MS. The fragmentation patterns for the analyzed peptide fragments for the mutant peptide (#3*) detected in
fibroblasts from the patient (left panel) and the heavy-labeled peptide that was spiked into the sample (right panel) are shown. The graphs show the peaks for the
different fragment ions in corresponding colors. (D) Peptides used for SRM analysis. Bars show the two HSP10 alleles of the patient with position of the peptides and
the mutation site. Peptides #1 and #2 are common to wild type and p.Leu73Phe HSP10 and the peptides spanning the mutation site (#3 wild type and #3*, mutant)
are depicted. (E) Quantification of HSP10 in patient and control fibroblasts. The two peptides common to both wild type and p.Leu73Phe HSP10 (#1 and #2) and the
peptide with wild type sequence spanning the mutation site (#3) were quantitated by SRM analysis as described in Materials and Methods. The mean of the
quantitated amounts of the three peptides measured in three different control fibroblast cultures were set to 100% and the mean amounts measured in three patient
cell cultures grown in parallel were expressed as percentage of these. Error bars denote standard deviation of the mean.
respiration (Supplementary Figure S4D) as well as basal
extracellular acidification rate (data not shown) between patient
and control fibroblasts were observed. This suggests that
HSP10 deficiency did not have a major effect on mitochondrial
respiratory chain activity and balance between mitochondrial
respiration and anaerobic glycolysis.
DISCUSSION
Exome sequencing of the patient with infantile spasms and
developmental delay described here detected heterozygosity for
a de novo mutation in the HSPE1 gene and chromosomal
microarray analysis detected a de novo deletion affecting the
TANC2 gene. Expression levels of the TANC gene family
genes TANC1 and TANC2 have been indicated to regulate the
density of dendritic spines and excitatory synapses (Han et al.,
2010) and diagnostic exome sequencing identified a de novo
TANC1 missense variation in one patient with severe intellectual
disability (de Ligt et al., 2012). Both the HSP10 missense
mutation and the loss of one TANC2 allele may potentially be
disease-associated. Because the HSPE1 gene encoding the small
subunit of the mitochondrial HSP60/HSP10 chaperonin complex
is essential for cell function and mutations in its complex partner
HSP60 have been associated with neurological diseases, we have
in the present study focused on investigating the effects of the
HSP10-p.Leu73Phe mutation.
The odds for accidentally finding a de novo mutation in a
specific gene are small. Data from exome sequencing predict
on average one de novo missense mutation per exome per
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FIGURE 4 | Protein levels of selected mitochondrial proteins in patient and control fibroblasts. (A) Levels of peptides for HSP60, MCAD, VDAC, and SOD2
were measured by SRM-MS. The quantitated amounts of all peptides measured in three different control fibroblast (open bars) were set to 100% and the amounts
measured in three parallel grown patient fibroblast cultures (filled bars) were expressed as percent fraction of these. Error bars denote standard deviation of the mean.
T-testing showed that the levels of the SOD2 peptides were significantly decreased (p < 0.05) in patient fibroblasts, while the peptides for MCAD, HSP60, and VDAC
were not significantly different in patient compared to control fibroblasts. (B) Mitochondrial superoxide levels. Superoxide levels were determined using the fluorescent
superoxide reporter MitoSOX. The left graph shows the histogram from one analysis; open peak: control, closed peak: patient. The right graph shows average mean
fluorescence intensities measured from three independent cultivations and analyses of control fibroblasts and parallel cultivations of the patient fibroblast. Error bars
represent SEM for the three respective replicates.
generation (Veltman and Brunner, 2012; Alkuraya, 2016). Given
this number, the length of the HSP10 coding region with 306
bases, the total human exome length with approximately 3.107
bases, and the world population at currently approximately 7.5
× 106 people, one can statistically expect 27 currently living
individuals carrying a de novo mutation in the HSPE1 exome.
A considerable fraction of these would be synonymous, so only
a handful of individuals will have missense or premature stop
codon variations in the HSPE1 gene.
Inspection of the mutation site in the structure of the human
HSP60/HSP10 complex showed that leucine-73 of HSP10 is not
localized in the domain that interacts with HSP60 subunits in the
complex. Rather, it is situated in the central part of the HSP10
structure, tightly packed by residues within the same HSP10
subunit. The phenylalanine that replaces leucine in the mutant
protein can apparently be accommodated in the structure,
but, because it is more bulky, it requires rearrangements.
Such rearrangements of the domain are expected to impair
folding and stability. Our in vitro analysis of recombinant
HSP10-p.Leu73Phe protein showed that although this protein
could be recombinantly expressed and purified in a fully
functional form, its thermal stability was indeed profoundly
decreased and its spontaneous refolding after denaturation was
impaired. Although, the decreased melting temperature of the
HSP10-p.Leu73Phe protein determined under in vitro conditions
was well above 37◦C, we show that the mutant HSP10 protein
displays increased susceptibility to proteolytic attack at 37◦C and
physiological pH.
Our observation that posttranslational import of the HSP10-
p.Leu73Phe protein into isolated mitochondria was more
efficient than import of the wild type HSP10 protein was
surprising. However, it has been shown for some other proteins
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that mutations destabilizing the conformational structure
of precursor proteins in the cytosol enhances their post-
translational import into mitochondria (Vestweber and Schatz,
1988). Protein import through the mitochondrial outer and
inner membrane as well as degradation by the ATP dependent
proteases Lon and ClpXP in the mitochondrial matrix require
previous unfolding of the transported/degraded polypeptide
(Lee et al., 2001; Prakash and Matouschek, 2004; Maurizi
and Stan, 2013). Thus, what at first sight appears to be
counterintuitive, likely reflects that the decreased conformational
stability renders the mutant HSP10 protein both more prone
to be transported through the mitochondrial import system
and more prone to degradation by mitochondrial proteases. In
line with this, the steady state levels of the HSP10-p.Leu73Phe
protein in the patient fibroblasts were much lower than those
of the HSP10-p.wt protein. Because transcript levels of the
mutant allele appeared unchanged and—given its position in the
transcript—because an effect of the mutation on translation is
unlikely, this suggested that the decreased level of the HSP10-
p.Leu73Phe protein is due to higher susceptibility to proteolytic
degradation.
Given the measured decreased Hsp10 to HSP60 protein ratio,
we wondered what effects this could potentially have? The
genes encoding HSP60 and HSP10, respectively, of eukaryotes
from C. elegans to humans are organized in a head-to-head
arrangement with a common bidirectional promoter (Ryan
et al., 1997; Bross et al., 2013). Furthermore, in bacteria the
corresponding genes encoding the large and small chaperonin
subunits are typically organized in an operon under control
of a common promoter (Lund, 2009). These architectures may
provide transcription of both chaperonin genes at a fixed
ratio suggesting that this ratio is crucial for correct function
of chaperonin complexes. It has indeed been shown that the
kinetics of in vitro refolding of malate dehydrogenase by the
HSP60/HSP10 complex depended on the HSP10 to HSP60
ratio (Levy-Rimler et al., 2001). Maximum refolding rate was
obtained at approximately 2:1 HSP10: HSP60 molar ratio and
clearly lower refolding was observed at a ratio of to 1:1. Levy-
Rimler et al. also presented evidence that HSP10 stabilizes
the double-ring conformation of human HSP60. Thus, the
observed almost 2-fold decrease of the HSP10/HSP60 ratio
would be expected to compromise the function and capacity
of the HSP60/HSP10 complex to assist folding and result in
significant impairment of folding of those proteins that are
most dependent on folding assistance by the HSP60/HSP10
complex.
We have previously shown that folding of SOD2, the
superoxide dismutase in the mitochondrial matrix, was
dramatically compromised in mice that express half levels
of HSP60 due to heterozygosity for a knock-out allele of the
murine Hspd1 gene (Magnoni et al., 2014). Furthermore, we
could demonstrate physical interaction of SOD2 with the
HSP60/HSP10 complex. As expected, our analyses of the
patient fibroblasts studied here showed that SOD2 protein
levels were significantly decreased. Decreased SOD2 protein
levels were not caused by decreased SOD2 transcript levels
as shown by qRT-PCR analysis. This is consistent with the
notion that SOD2 is one of the proteins in the mitochondrial
matrix, which particularly depend on the HSP60/HSP10
complex to acquire its native state. The native state of the
SOD2 enzyme is a homotetramer with a manganese atom
in the active site of all four subunits (Borgstahl et al., 1992).
Decreasing either component of the HSP60/HSP10 complex
appears to impair SOD2 protein folding and entail degradation
of SOD2 folding intermediates. Recombinant expression
experiments in E. coli have shown that yield, metal content
and activity of human SOD2 were increased when the bacterial
HSP60/HSP10 homolog GroEL/GroES was co-overexpressed
(Hunter and Hunter, 2013). Assistance by the HSP60/HSP10
chaperonin complex for folding and concomitant metal
incorporation may be a particularly crucial step that it is
impaired when the capacity of HSP10/HSP60 complex is
limiting.
No monogenic human disease caused by mutations in the
SOD2 gene has been described yet. A series of knockout
mouse models for the Sod2 gene have been investigated
mostly in context with research of the mitochondrial free
radical theory of aging (Barja, 2013). Knock-out of both
Sod2 alleles leads to lethality within 18 days of birth in
different strain backgrounds (reviewed in Marecki et al., 2014).
Mice with only one Sod2-knock-out allele that express half
levels of the SOD2 protein had normal life-span and no
overt phenotype, but displayed increased oxidative damage
as well as increased apoptosis tendency (Strassburger et al.,
2005; Wenzel et al., 2008). The SOD2 levels we measured
in the patient fibroblasts were less than 50% of controls
suggesting more severe consequences than those modeled in
the heterozygous SOD2 knockout mice. Damage caused by high
levels of reactive oxygen species is especially critical for neuronal
tissue that only to very limited extent can be regenerated. A
consequence of decreased SOD2 activity would be increased
superoxide levels in the mitochondrial matrix and we indeed
measured a significant increase in matrix superoxide using
the mitochondrial matrix fluorescence reporter MitoSOX. This
may advocate that increased superoxide levels represent one
of the disease-associated molecular phenotypes in the current
case.
The question remains whether increased superoxide levels
are the only major effect of the HSP10 mutation in the patient
cells investigated in our study. The observation of intermittently
increased levels of various disease marker metabolites related
to mitochondrial enzyme deficiencies in the patient suggests
that the SOD2 deficiency is probably only one of several
consequences of the skewed HSP10/HSP60 ratio. Our further
analysis of the patient fibroblasts for general mitochondrial
factors like mitochondrial membrane potential, cellular redox
status and mitochondrial respiratory chain activity showed no
significant differences compared to controls suggesting that
potential additional effects on these parameters are subtle or not
manifesting in fibroblasts.
We also analyzed whether the levels of medium-chain acyl-
CoA dehydrogenase (MCAD) were affected in the patient cells.
MCAD is an enzyme involved in mitochondrial fatty acid
oxidation that has previously been shown to interact with the
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HSP60/HSP10 complex (Yokota et al., 1992; Saijo et al., 1994).
Yet, our investigations showed similar MCAD protein levels in
the patient and control fibroblasts, suggesting that folding of this
interactor is less affected by the decreased HSP10 levels. The
interactors of the homologous bacterial GroEL/GroES complex
have been characterized and distinguished into classes depending
on the length of the time period they interact (Ewalt et al.,
1997). Among approximately 250 interactors a core set of about
85 proteins was shown to be highly dependent on folding
assistance by the chaperonin complex (Kerner et al., 2005). Such
an inventory of interactors and validation of their dependence
on the function of the HSP60/HSP10 complex would be helpful
for pinpointing further candidates, but is still lacking for the
mammalian HSP60/HSP10 complex.
In conclusion, as we did not investigate potential effects of
the deletion of parts of the TANC2 gene, we can currently not
exclude that it is disease associated. However, based on the results
from a battery of in vitro and ex vivo studies, we make the case
that heterozygosity for the HSP10-p.Leu76Phe de novo missense
mutation potentially could be responsible for the neurological
and developmental disorder of the patient reported here.
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Supplementary Figure S1 | Mass spectrometric analysis of HSP10
full-length and core bands. (A) Full-length and core bands from a limited
proteolysis experiment like the one shown in Figure 2D were excised and
prepared for mass spectrometry (LC-MS/MS). Elution profiles for detected
peptides are shown in (A). The arrows point to peptides that are highlighted in the
corresponding colors in (B). Green arrow: amino acids 41–54
(VLQATVVAVGSGSK), magenta arrows: amino acids 71–80 (VL-x-PEYGGTK with
Leu (wt) or Phe (mutant), respectively, at the “x”-position), blue arrow: amino acids
9–15 (FLPLFDR). (B) HSP10 subunit R in schematic representation. Position of
lysine and arginine residues are highlighted in yellow, the mutated leucine-73
residue is shown as sticks in red and the amino (N) and carboxy-terminal (C)
positions are depicted. The representation was made with Discovery Studio
Visualizer v.4.5 (Biovia) using PDB coordinates for the human HSP60/HSP10
complex (4PJ1).
Supplementary Figure S2 | RT-qPCR quantitation of transcript levels. RNA
purified from patient and three individual control fibroblasts was reverse
transcribed into cDNA and subjected to quantitative analysis with qPCR TaqMan
assays. Error bars represent standard error of mean for biological triplicates. Filled
bars: Patient, open bars: mean from three pooled controls. P-values were
obtained with student’s t-test and showed no significant differences.
Supplementary Figure S3 | Mitochondrial morphology. Fibroblasts from the
patient and a healthy control individual were seeded at 50% confluence in 6-well
plates 24 h before the analysis. The fibroblasts were stained with 100 nM
Mitotracker Green for 30 min at 37◦C. Pictures were obtained with the EVOS
FLoid Cell Imaging Station as described in materials and methods. Two
representative pictures each of the control (left panel) and the patient (right panel)
fibroblasts are shown.
Supplementary Figure S4 | Cellular viability, thiol redox status,
mitochondrial membrane potential, and mitochondrial oxygen
consumption profiling. (A) Cellular viability measured as the percentage of
viable cells. (B) Cellular thiol redox status measured as intensity of the Vita-Bright
48 (V.B-48) fluorescent dye. V.B-48 becomes fluorescent when it reacts with
reduced thiols which are used to quench molecules that are damaging to the cell,
such as free radicals, and are used as a measurement for general cellular
oxidative/reduced status. (C) The mitochondrial membrane potential measured as
the red/green ratio of the fluorescent dye JC-1. An assay control (control cells
treated with the uncoupler CCCP) is also shown. (D) Mitochondrial oxygen
consumption rate profiling. Oxygen consumption rate (OCR) of patient and control
fibroblasts in dependence of addition of modulators [1: oligomycin (inhibitor of
complex V); 2: FCCP (uncoupler); 3: antimycin A and rotenone (inhibitors of
complex I and III, respectively)] was measured using the Mito Stress test-kit and
the Seahorse XFe96 extracellular flux analyzer. Samples from 3 different control
fibroblasts and 3 independently grown cultures of the patient fibroblasts were
analyzed. OCR was normalized to total protein amount quantified by the Bradford
assay.
Supplementary Table S1 | Oligonucleotide primer sequences.
Supplementary Table S2 | Genes investigated in exome sequencing.
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APPENDIX
Extended Clinical Patient Information
The patient presented at 3months of age with spasticmovements.
An EEG diagnosed infantile spasms. A brain MRI did not
show any abnormalities. At the age of 3, he was diagnosed
with myoclonic and tonic epilepsy. He came to the attention of
medical genetics at 7 months of age. Developmental milestones
were globally delayed. He rolled over at 7 months, sat at 16
months, and walked at 3½years. At 17 months he said only a
single word. At the age of 4, he is still largely nonverbal. He
was found to have intermittent exotropia and cortical visual
impairment on ophthalmologic examination.Mild hepatomegaly
and slightly course features were noted by neurology, prompting
the lysosomal screening. These were not appreciated by genetics.
Aside from mild macrocephaly and a thin upper lip, the patient
did not demonstrate dysmorphic features on examination by
genetics.
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